AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03275376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Atorvastatin or placebo will be administered according to randomized allocations.
Study NCT03173976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic acid, a member of bisphosphonate class, inhibits bone resorption.
Study NCT04058561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MAGEC® Spinal Bracing And Distraction System
Description: The magnetically controlled growth rod (MCGR) system is a remotely distractible, magnetically controlled growing rod. The remote capabilities allow for less invasive and less time-consuming outpatient distraction visits, which solves many of the problems facing current growing rod technologies. The MCGR system allows for more frequent lengthenings, and the implanted growing rods can be lengthened more often, which allows MCGR to better approximate normal spine growth compared to Traditional Growing Rods.
Study NCT04058561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAGEC® Spinal Bracing And Distraction System
Description: The magnetically controlled growth rod (MCGR) system is a remotely distractible, magnetically controlled growing rod. The remote capabilities allow for less invasive and less time-consuming outpatient distraction visits, which solves many of the problems facing current growing rod technologies. The MCGR system allows for more frequent lengthenings, and the implanted growing rods can be lengthened more often, which allows MCGR to better approximate normal spine growth compared to Traditional Growing Rods.
Study NCT02292979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 25mg/m2
Study NCT02292979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25mg/m2
Study NCT01810913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT01810913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT01810913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT01810913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT01810913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01810913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT01810913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT01810913 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT01810913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01810913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT01810913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02292979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: 10mg/m2
Study NCT02292979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine
Description: 6mg/m2
Study NCT04390425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental - Limb Occlusion pressure
Description: This intervention involves lower tourniquet pressure than the standard of care. There is no change to tourniquet time or how the surgery is performed.
Study NCT02879695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02879695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV
Study NCT02879695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT02879695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02879695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03159169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Description: Implantation of SCS electrodes and stimulator according to clinical standards
Study NCT04353999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket sealing by diode laser photocoagulation
Description: tooth extraction followed by socket grafting with bovine bone xenograft and finally sealed using 980 nm diode laser photocoagulation applied in a non-contact mode with a poer output of 1 watt in a continuous wave mode for 3-5 minutes
Study NCT04353999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: socket sealing with dense polytetrafluroethylene membrane
Description: tooth extraction followed by socket grafting with bovine bone xenograft and finally sealed by a non-resorbable dPTFE membrane that is stabilized by suturing to the soft tissue margins of the socket
Study NCT02441491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given by vein once a day for four straight days.~Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, by vein once every day to try to help your blood cells grow faster.
Study NCT05706246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: diagnostics
Description: Serum tryptase levels were evaluated in all suspected children with perioperative hypersensitivity
Study NCT01561300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition intervention study with a black tea extract
Description: Tea extract: 1800 mg/day standardized Brooke Bond black tea extract equivalent to 400 mg flavonoids dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days tea will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups or tea, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added.
Study NCT01561300 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition intervention study with a control
Description: Control: 1800 mg/day of a powder that gives a flavoured beverage with a color similar to black tea dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days control will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups of control, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added.
Study NCT02221505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOP628
Study NCT06179277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrefGel® + Emdogain®
Description: Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®) and application of 0.3 mL Emdogain® to root surface with 27-gauge needle
Study NCT06179277 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PrefGel®
Description: Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®)
Study NCT03300271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application for self monitoring
Description: Participants in this group will be introduced to use a mobile application to self record and monitor their life style behaviors. They will be also be provided education same as the control group.
Study NCT03300271 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Participants in this group is provided education. Education includes information of metabolic syndrome, methods to manage lifestyle (diet, physical activity).
Study NCT03300271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application for personal coaching
Description: Participants in this group will be introduced to use a mobile application. Personal coaches such as dietitian, sports manager encourage to improve their life style behaviors. They will be also be provided education same as the control group.
Study NCT01281254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG386 plus PLD
Description: AMG 386 is a first in class investigational anti angiogenic drug that provides potent and selective inhibition of angiopoietins. AMG 386 is designed to inhibit angiogenesis by sequestering Ang1 and Ang2, thereby preventing their interaction with the Tie2 receptor. Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug. PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
Study NCT01281254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus PLD
Description: Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug.~PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)
Study NCT01928589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PBI with sequential chemotherapy
Description: 270 cGy x15
Study NCT01928589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PBI with concurrent chemotherapy
Description: 270 cGy x15 concurrent with chemotherapy of the treating medical oncologist's choice
Study NCT00585442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: 1.0 mcg daily
Study NCT00585442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01151059 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Trivalent subunit inactivated flu vaccine, Formulation 2010-2011
Description: This phase II is performed as a multicenter study site in non-elderly adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22).
Study NCT03971240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: evacuation of traumatic acute subdural hematoma
Description: craniotomy will be done with evacuation of the hematoma
Study NCT01835574 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conditional cash transfer and cognitive-behavioral aftercare
Description: The intervention combines a 12-week conditional cash transfer (CCT) intervention with 4-weeks of cognitive-behavioral group aftercare (AC) among women who use ATS. CCT includes thrice weekly urine screening for 12 weeks; participants receive $ for ATS-negative screens. Those with 3 negative screens in a week participants receive a cash bonus, which increase per month to mitigate habituation to the CCT reward schedule. Women who complete >=50% of ATS negative screening visits may participate in a 4-week, cognitive-behavioral AC group delivered immediately after CCT, which includes: 1) experiential group exercises; 2) didactic recovery skills training; 3) meditation and relaxation training; and 4) a ''lucky draw'' which is a form of CCT that provides positive reinforcement for group attendance.
Study NCT01825486 — intervention group
Intervention type: BEHAVIORAL
Intervention: accidental falls
Study NCT04599023 — intervention group
Intervention type: DEVICE
Intervention: MSPT
Description: The MS Performance Test (MSPT) software tool and accompanied hardware is an iPad®-based assessment tool, developed via collaboration between Biogen and the Cleveland Clinic Mellen Center, and designed to objectively quantify the major motor, visual and cognitive function data, and quality of life outcomes, associated with MS and related disorders.These assessment modules of the MSPT are self-administered by MS patients at the point of care and incorporate and expand upon previously validated measures of the MSFC.
Study NCT02376725 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phaco/IOL
Description: Phaco/IOL refers to extracapsular cataract extraction (using phacoemulsification) and intraocular lens implantation
Study NCT02376725 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phaco/IOL + goniosynechialysis
Description: Phaco/IOL refers to extracapsular cataract ectraction (using phacoemulsification) and intraocular lens implantation. Goniosynechialysis refers to mechanical breaking of peripheral anterior synechiae using a spatula and goniolens to view the drainage angle structures.
Study NCT01342354 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation
Description: Escalating Doses of SBRT in periods of three doses over 10 days
Study NCT01854216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch 1mg / 24 hours
Description: Rotigotine transdermal patch, repeated dose application over 24 hours; 1 mg / 24 hours
Study NCT02292979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: 6mg/m2
Study NCT02292979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: 375mg/m2
Study NCT02292979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 375mg/m2
Study NCT02292979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: 1.2 mg/kg
Study NCT03591471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycosides Of Tripterygium Wilfordii Hook(GTW)
Description: For severe HSPN GTW is 2mg/kg/d for the first 2 weeks , continued with 1.5mg/kg/d (maximum to 90mg/d) for another 2 weeks; For light HSPN GTW is 1.5mg/kg/d(maximum to 90mg/d) for 4 weeks.~Both the 2 types are continued with 1mg/kg/d of GTW for another 4 weeks . Besides,Sulfotanshinone Sodium Injection,Qingrezhixue graunles,Chinese herbs by syndrome differentiation are plused at the same time
Study NCT03591471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfotanshinone Sodium Injection
Description: Intravenous drip of Sulfotanshinone Sodium Injection with the dosage of 1mg/kg/d(maximum to 50mg), combined with 100-250ml 5% Glucose Solution (G.S) for 2 weeks in both the light and serious type of TCM group.
Study NCT03591471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbs based on syndrome differentiation
Description: For both the light and serious type of HSPN in TCM group,five traditional Chinese medicine patterns of syndrome are classified on the main pathogenesis Blood Stasis: based on Qingre Zhixue granule,for wind-heat complicated with blood stasis, add Forsythia, Honeysuckle,;for blood-heat complicated with blood stasis,add Buffalo horn,Comfrey; for yin deficiency complicated with blood stasis, add Rhizoma anemarrhenae,Cortex phellodendri;for both qi and yin deficiency complicated with blood stasis,add Astragalus, Heterophylla;for damp-heat complicated with blood stasis,add Scutellaria baicalensis,Lalang Grass Rhizome.
Study NCT03591471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone Acetate Tablets
Description: Prednisone Acetate Tablets are necessary for serious HSPN in controlled group,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）
Study NCT03591471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benazepril Hydrochloride Tablets
Description: In controlled group, Benazepril Hydrochloride Tablets are used for both the light and serious type with the dosage of 5-10mg/d(10mg/d for children with weight above 30kg) ,12 weeks in total.
Study NCT03591471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Molecular Weight Heparin Calcium Injection
Description: In controlled group,Low Molecular Weight Heparin Calcium Injection are used for both the light and serious type with the dosage of 100u/kg/d by hypodermic injection for 2 weeks
Study NCT03591471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyridamole Tab 25 MG
Description: In controlled group,Dipyridamole Tab 25 MG are used for both the light and serious type of HSPN with the dosage of 3mg/kg/d ,3 times a day,12 weeks in total.
Study NCT01854216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch 2 mg / 24 hours
Description: Rotigotine transdermal patch, repeated dose application over 24 hours; 2 mg / 24 hours
Study NCT01854216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch 4 mg / 24 hours
Description: Rotigotine transdermal patch, repeated dose application over 24 hours; 4 mg / 24 hours
Study NCT03620578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R followed by Nivolumab
Description: 5 induction cycles of DA-EPOCH-R protocol, for patient with Deauville imaging response criteria proven complete metabolic response followed with one year Nivolumab consolidation therapy
Study NCT01986192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Study NCT01986192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study NCT03591471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chinese medicine placebo
Description: In controlled group,take a potential necessary for patients who come to the hospital of TCM to take traditional Chinese medicine in consideration, we add the traditional Chinese medicine placebo in controlled group.
Study NCT00892853 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CT of the bones
Description: A CT scan will be performed on one arm and one leg for the purpose of acquiring images for this research study.
Study NCT00872534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid
Description: 325mg once a day for 7 days
Study NCT04487535 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cytokine level
Description: Serum cytokine level will be measured before surgery, 72nd after surgery and 6 weeks after surgery
Study NCT00872534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: 325mg once a day for 7 days
Study NCT00612417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402
Description: Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402
Study NCT00612417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402
Description: Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402
Study NCT00712725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3207- 2.5 mg
Description: Arm 1: MK3207 2.5 mg taken after migraine onset.
Study NCT00712725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3207- 5 mg
Description: Arm 2: MK3207 5 mg taken after migraine onset.
Study NCT00712725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3207- 10 mg
Description: Arm 3: MK3207 10 mg taken after migraine onset.
Study NCT00712725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3207- 20 mg
Description: Arm 4: MK3207 20 mg taken after migraine onset.
Study NCT00712725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3207- 50 mg
Description: Arm 5: MK3207 50 mg taken after migraine onset.
Study NCT00712725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3207- 100 mg
Description: Arm 6: MK3207 100 mg taken after migraine onset.
Study NCT00712725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: Placebo taken after migraine onset.
Study NCT01896076 — intervention group
Intervention type: OTHER
Intervention: ultrasound evaluation of caudal space
Description: After induction of general anesthesia, the patients were placed in the lateral position. The ultrasound evaluation include transverse and longitudinal view.~First, investigators place the transducer at the sacral cornua to obtain a transverse view.~In the transverse view, the distance between two cornua and the depth of caudal space at the sacral hiatus were measured. In the longitudinal view, the distance from the skin to the sacrococcygeal membrane and the optimal angles and the safety distance for needle insertion depending on the points of insertions were measured. From the end of dura sac to the sacral hiatus were regarded as safety distance for the needle insertion during caudal block.
Study NCT00535704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong African American Families-Teen Program
Description: 5 week educational program for teens and their caregivers.Each meeting lasts approximately 2 hours.
Study NCT00535704 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: FUEL
Description: 5 week educational program for teens and caregivers. Each weekly session lasts approximately 2 hours